Chronic Neonatal Tiagabine Treatment Attenuates Hippocampal Abnormalities in the Ts65Dn Mouse Model of Down Syndrome
Journal of Neurochemistry · 2026-11 · 170 (11)
DOI: 10.1111/jnc.70584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 05.11.2026. Verfasst von Emilio Varea und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurobiology Unit, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Nipecotic Acids, Hippocampus, Down Syndrome. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Fondation Jérôme Lejeune, Ministerio de Ciencia e Innovación, Generalitat Valenciana.
Abstract (Originalsprache)
Down syndrome (DS) is a genetic aneuploidy characterized by a variable phenotype that includes a certain degree of intellectual disability. These alterations have been associated with impaired cell proliferation, reduced structural plasticity, and imbalances in inhibitory‐excitatory neurotransmission. Adults with DS exhibit increased inhibition, whereas fetuses and newborns display deficits in inhibitory signaling. In this study, we confirmed that new‐born Ts65Dn mice, the most widely used model of DS, show a reduction in inhibitory synapses. We treated Ts65Dn pups daily for 4 weeks after birth with tiagabine, a GABA transporter 1 inhibitor that increases extracellular GABA levels, in an attempt to restore normal inhibition. This early intervention restored the total number of synapses and normalized the excess of inhibitory contacts previously described in the adult Ts65Dn hippocampus. The expression of plasticity‐related molecules, such as PSA‐NCAM, increased in parallel with the recovery of spine density on granule cells and thorny excrescences on CA3 pyramidal neurons. Moreover, cell proliferation, neurogenesis, and cellular activity were restored to control levels. Overall, these results indicate that early intervention targeting GABAergic neurotransmission during a critical developmental window may be an effective strategy to reverse hippocampal alterations in Ts65Dn mice and suggest that GAT‐1 may have therapeutic potential for individuals with DS. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neurobiology Unit, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Valencia, Spain.
- CIBERSAM, Spanish National Network for Research in Mental Health, Madrid, Spain.
- Institute of Research of the Clinic Hospital From Valencia (INCLIVA), Valencia, Spain.
ORCID-Profile: Emilio Varea, Elena Gomez-Gomez, Raúl Ballestín, José Miguel Blasco-Ibáñez, Juan Nacher
Förderung
- Fondation Jérôme Lejeune
- Ministerio de Ciencia e Innovación
- Generalitat Valenciana
Zitieren
APA
Varea, E., López-Hidalgo, R., Gomez-Gomez, E., Artieda, L., Ballestín, R., Vega, J., Blasco-Ibáñez, J. M., Crespo, C., & Nacher, J. (2026). Chronic Neonatal Tiagabine Treatment Attenuates Hippocampal Abnormalities in the Ts65Dn Mouse Model of Down Syndrome. Journal of Neurochemistry, 170(11). https://doi.org/10.1111/jnc.70584
Vancouver
Varea E, López-Hidalgo R, Gomez-Gomez E, Artieda L, Ballestín R, Vega J, et al. Chronic Neonatal Tiagabine Treatment Attenuates Hippocampal Abnormalities in the Ts65Dn Mouse Model of Down Syndrome. Journal of Neurochemistry. 2026;170(11). doi:10.1111/jnc.70584
BibTeX
@article{Varea2026,
author = {Varea, Emilio and López-Hidalgo, Rosa and Gomez-Gomez, Elena and Artieda, Luka and Ballestín, Raúl and Vega, Jessica and Blasco-Ibáñez, José Miguel and Crespo, Carlos and Nacher, Juan},
title = {Chronic Neonatal Tiagabine Treatment Attenuates Hippocampal Abnormalities in the Ts65Dn Mouse Model of Down Syndrome},
journal = {Journal of Neurochemistry},
year = {2026},
volume = {170},
number = {11},
doi = {10.1111/jnc.70584}
}
EUVIMED